NCT01541852View on ClinicalTrials.gov

Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen.

PHASE2CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Chronic Obstructive Pulmonary Disease
Interventions
DRUG

Losmapimod

One tablet of Losmapimod 7.5mg twice daily

DRUG

Placebo

One tablet twice daily

Trial Locations (2)

CB2 0QQ

Cambridge University Hospitals NHS Foundation Trust, Cambridge

SW3 6NP

Royal Brompton & Harefield NHS Foundation Trust, London

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

Technology Strategy Board, United Kingdom

OTHER

collaborator

GlaxoSmithKline

INDUSTRY

collaborator

Royal Brompton & Harefield NHS Foundation Trust

OTHER

collaborator

University of Cambridge

OTHER

lead

Cambridge University Hospitals NHS Foundation Trust

OTHER

NCT01541852 - Losmapimod in Chronic Obstructive Pulmonary Disease Patients Stratified by Fibrinogen. | Biotech Hunter | Biotech Hunter